Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $20.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target increased by Morgan Stanley from $18.00 to $20.00 in a report published on Friday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright decreased their price objective on Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, September 3rd. Guggenheim decreased their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. TD Cowen lowered their target price on Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, September 3rd. Finally, Citigroup upped their target price on Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $34.42.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $14.51 on Friday. The firm’s 50 day moving average is $23.88 and its 200-day moving average is $24.43. The company has a market capitalization of $1.43 billion, a PE ratio of -2.48 and a beta of 0.31. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm’s revenue was up 28.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.17) earnings per share. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical will post -3.98 EPS for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Assenagon Asset Management S.A. increased its stake in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after purchasing an additional 2,057,951 shares during the last quarter. GW&K Investment Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 19.6% in the 4th quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock valued at $31,634,000 after purchasing an additional 225,238 shares during the period. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $29,004,000. Finally, Bank of America Corp DE acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $38,347,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted full approval to FAYUVI for pediatric patients with Sanfilippo syndrome Type A, also known as MPS IIIA. It is the first approved treatment for the fatal neurodegenerative disease, creating a new commercial opportunity for Ultragenyx where no prior therapy existed. Clinical data showed durable benefit, including a 23.5-point cognitive advantage versus natural history in the pivotal analysis. Ultragenyx Announces Approval of FAYUVI Gene Therapy
• Positive Sentiment: FAYUVI carries a reported $3.95 million list price, potentially making it a significant revenue contributor despite the disease’s small patient population. Ultragenyx expects shipments to qualified treatment centers within 30–60 days and will provide insurance and treatment-access support through its UltraCare program. Ultragenyx Sets $3.95m List Price for Fatal Rare Disease Therapy
• Positive Sentiment: The approval is Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company also received a Priority Review Voucher, which could accelerate development or potentially have financial value. US FDA Approves Ultragenyx’s Gene Therapy
• Positive Sentiment: Analysts raised targets after the approval: Cantor Fitzgerald and Canaccord Genuity moved to $39, Citi to $32, and Morgan Stanley to $20. Citi and Canaccord maintained bullish ratings, while Morgan Stanley remained equal weight. Ultragenyx Stock Jumps on Fayuvi Approval and Analyst Target
• Neutral Sentiment: The commercial opportunity is promising but limited by the ultra-rare population. Successful sales will depend on identifying eligible children, establishing treatment centers, securing insurer reimbursement, and managing the complexity of one-time gene-therapy administration.
• Negative Sentiment: FAYUVI’s label includes risks such as liver toxicity, low platelet counts, infusion reactions, thrombotic microangiopathy, and potential malignancy. Long-term safety and real-world adoption remain important uncertainties.
• Negative Sentiment: A Pomerantz law-firm investigation adds an overhang, while the earlier failed Angelman syndrome trial remains a reminder of Ultragenyx’s clinical-development risk. Pomerantz Investor Alert

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.